Funding to Support Medical Products Manufacturing in WA
A new voucher scheme from the MTPConnect WA Life Sciences Innovation Hub is providing a major boost for medical products manufacturing in Western Australia.
Under the scheme, five WA-based companies have been awarded a total of $450,000 to accelerate innovation projects requiring advanced manufacturing capabilities.
Matched with cash co-contributions of $600,000, the initiative is injecting more than $1 million into WA’s medical technology, biotechnology and pharmaceutical sector to drive job creation and economic growth.
- OncoRes Medical Pty Ltd - clinical feasibility of a diagnostic imaging device for cancer surgery
- Proteomics International Pty Ltd - manufacturing next generation in vitro device to predict diabetic kidney disease
- SynGenis Pty Ltd - establishing certified oligonucleotide (DNA and RNA) manufacturing capabilities in WA
- VeinTech Pty Ltd - VeinWave: improving first pass cannulation success
- VitalTrace Pty Ltd - developing Perth into Australia's flagship precision healthcare biosensor development and manufacturing hub
This new Program aims to capitalise on WA’s significant capability in innovative medical technology and pharmaceutical (MTP) research and support the acceleration of this research into the development and manufacture of products such as medical devices (physical and/or digital), diagnostics, biologics and pharmaceuticals.
Funding is being made available through the MTPConnect WA Life Sciences Innovation Hub, which is co-funded through the WA Government’s New Industries Fund and the University of Western Australia to accelerate economic growth and create new jobs and industries.
About the awardees:
- OncoRes Medical Pty Ltd: With a focus on improving the accuracy of breast conserving surgery, OncoRes Medical is driven by a mission to eliminate repeat operations after breast conserving surgery. OncoRes Medical is developing key pre-production manufacturing activities in WA, advancing their development of a novel diagnostic imaging system that guides surgical clearance of cancer in breast conserving surgery.
- Proteomics International: Established in 2001, Proteomics International is recognised as a leader in the field of proteomics, developing and commercialising diagnostic tests for chronic diseases. The company is developing WA-based manufacturing capability of the PromarkerD diagnostic, which can predict the onset of diabetic kidney disease in patients with Type 2 diabetes.
- SynGenis Pty Ltd: Perth start-up SynGenis was established in late 2020 and now operates a large facility in Bentley Technology Park to manufacture high quality oligonucleotides (DNA and RNA) for the Australian and New Zealand market, and international customers. The company is seeking to expand their existing oligonucleotide manufacturing capabilities in WA to include ISO and GMP certification.
- VeinTech Pty Ltd: VeinTech aims to eliminate the guess work associated with cannulation, the most common invasive medical procedure. Their solution is a handheld ultraportable proof-of-concept prototype developed in partnership with a WA-based manufacturer designed to assist with visualising veins.
- VitalTrace Pty Ltd: Committed to empowering obstetricians and midwives to deliver the greatest outcomes for their patients, VitalTrace is developing a highly accurate biosensor to improve the safety for mothers and babies during childbirth. The voucher will support key pre-production manufacturing activities in WA.
All projects are due to be completed by 30 May 2022.
For further information contact MTPConnect’s Director Stakeholder Engagement WA Dr Tracey Wilkinson.